Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looking good today
Intraday gap on the 5 min?
Will it fill the gap?
If you believe in that stuff...
About time!
Is this the notorious Otc conartist Micheal Berger?
Where are the revs ???? This is a scam staying afloat with R/S,RUN IF U CAN !!!!!
Good eye ;) PSYC
PSYC .0059 Yes,nice chart with decent news as of late.I think We see this one in pennyland imo
OTC DISCLOSURE & NEWS SERVICE
From
To
PSYC Enters MOU to Acquire Technical420, LLC for $2.25M in Accretive TransactionPress Release | 08/16/2022
PSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Third Consecutive MonthPress Release | 08/03/2022
PSYC Strengthens Balance Sheet by Consolidating Notes with Reduced InterestPress Release | 07/19/2022
PSYC Provides Update on Psychedelic Spotlight’s Dynamic Q2 Year-over-Year Audience Growth of 708%Press Release | 07/11/2022
PSYC and Digital Acorn Ltd. Aim to Bring a First-of-its-Kind Psychedelic Hospitality-Focused Platform to MarketPress Release | 07/06/2022
PSYC Provides Encouraging Update on its Investment in The Conscious FundPress Release | 06/29/2022
GoDaddy Founder, Bob Parsons Details Journey of Healing Through Psychedelics in Exclusive Interview With PSYCPress Release | 06/15/2022
PSYC’s Psychedelic Spotlight Surpasses 1M Page View MilestonePress Release | 06/13/2022
https://www.barchart.com/stocks/quotes/PSYC/technical-chart?plot=CANDLE&volume=total&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);SRSI(14,14);WILLR(14,40);ADX(14);ACCUM;MACD(12,26,9);RSI(14,100);SMA(50)&sym=PSYC&grid=1&height=500&studyheight=100
glta
Took a position today. Like what I am seeing here. $PSYC chart is set to breakout.
Very strong and under the radar ;) PSYC
When can I cash out my stock? Someone please advise. I’d greatly appreciate anything feedback/advice that you can provide.Thanks!
Steady as she goes ;) PSYC
sure does look strong
PSYC .0055 Chart looking strong imo
https://www.barchart.com/stocks/quotes/PSYC/technical-chart?plot=CANDLE&volume=total&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);SRSI(14,14);WILLR(14,40);ADX(14);ACCUM;MACD(12,26,9);RSI(14,100);SMA(50)&sym=PSYC&grid=1&height=500&studyheight=100
glta
About PSYC Corporation
At PSYC Corporation we are integrating media, creativity, and technology to develop and deploy thought-provoking ideas and solutions that are fostering and transforming the approach to some of society’s most pressing matters.
PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, we believe investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.
We are dedicated to a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future.
PSYC Corp's Psychedelic Spotlight Surpasses One Million Page Views for Third Consecutive Month
August 03 2022 - 08:30AM
PSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Third Consecutive Month
LAS VEGAS, NV -- August 3, 2022 -- InvestorsHub NewsWire -- PSYC Corporation (OTCPink: PSYC) (“PSYC” or the “Company”), a media leader focused on the emerging psychedelic sector, announced that its flagship platform, Psychedelic Spotlight, surpassed one million Page Views in the month of July, as well as setting new monthly records for the following KPI’s: Page Views, Impressions, Organic Visits, and Click Thru Rate (CTR).
The accomplishment comes after Psychedelic Spotlight first surpassed one million Page Views in the months of May and June. This is the first time the Company achieved this milestone, and the development, combined with its ongoing top ranking on Google under the search category “psychedelic news,” further solidifies management’s claim to Psychedelic Spotlight being the most recognized and respected leader for psychedelic news, information, and unique perspectives within the sector.
Per the Company, Psychedelic Spotlight’s July 2022 operating highlights are as follows:
Page Views: 1.2M
Impressions: 1.58M
CTR: 6.6%
Organic Visits: 117.5K
July 2022 over July 2021 Growth: Page Views 639% | Impressions 298% | CTR 119%
“Psychedelic Spotlight was an obscure website with maybe 10-15 articles and editorials just two years ago, with neither an established brand identity nor audience. We are incredibly proud of our team for growing it into the juggernaut it is today,” said PSYC CEO, David Flores.
“Psychedelic Spotlight’s evolution into a formidable multimedia leader within the medicinal psychedelics sector is, in my opinion, providing PSYC with a tangible asset that not only lays the foundation for our longer-term growth initiatives, but also plays an active role in attracting and leveraging new opportunities that can directly impact some of our shorter-term initiatives. Even though nothing is definitive at this point in time, I am absolutely encouraged by the opportunities actively explored thus far by PSYC in Q3. Each of them, from my perspective, came to us as a direct result of the identity, audience, and value we established through Psychedelic Spotlight, which is why I remain cautiously optimistic for PSYC’s future.”
Psychedelic Spotlight Marketing Director Maria Holyanova touted the platform’s monthly performance. "Psychedelic Spotlight’s organic growth proves us capable of executing our strategies, even in trying times. Over the last month, our team updated its game plan, which ultimately led to a higher ranking for Psychedelic Spotlight on Google Search and Google News. This not only indicates adaptable working strategies in real time but also a growing interest in the potential benefits of psychedelics. As the audience for the psychedelic space continues to grow, Psychedelic Spotlight strives to not only deliver information in an unbiased and informative way, but also contribute to harm reduction and a healthier, happier society."
Psychedelic Spotlight Executive Director Swati Sharma elaborated on Psychedelic Spotlight’s growing influence on conversations within the psychedelic space. “Our ability to reach 1M+ page views for the platform and sustain them over the course of several months continues to prove that Psychedelic Spotlight is on an upward growth trajectory for the foreseeable future. Not only have we built this following, but we are consistently ranking at the top of Google through our organic growth, continuing to provide value for our own reach, trusted partners, and media affiliates. We are so excited about the impact we’ve had within the psychedelic sector, and we expect our influence will continue to grow as we incorporate more topics relating to health and wellness into our ever-evolving content and media strategies.
PSYC CFO Craig Schlesinger concluded with, “Psychedelic Spotlight’s year over year growth trends are undeniable. Last month the platform crossed the 100K Organic Visits milestone for the first time, and hit another record this month, exceeding 117K Organic Visits. Our audience continues to expand as interest in psychedelics spread and shed old stigmas. Moreover, investor demand for PSYC increased in July, as the stock gained 20% during the month, coupled with increased trading volume. Investors are definitely taking notice of Psychedelic Spotlight’s dynamic growth. With a recent study estimating the future value of the medicinal psychedelics sector at $7B+ by 2026, it’s an exciting time for Team PSYC.”
The charts provided below are for informational purposes only. Data sourced from Google Analytics.
https://lh6.googleusercontent.com/GlBLZuM3D6G7F4Dg7kJx0jPUx1-eEg1ERbgp48EWKTmiwIfTXxhRU-HstDkB9mEBHCD6D2Lkpwk1TnxHcojFrUaYEtQwtRJ8MLs83bLVCnv6ktFdDne_sxtS-V3DLk8MFfgjZTL0nM17_rITGjZ-u4Qhttps://lh5.googleusercontent.com/omIqfdsoKFYc3d8TkgiBYfiPBcn8_Ee-k531867b9eE48KIDh4DEQKGRN5rdfGxYNcKEiQrjXDv40nAS-atMwhWHcw9AsoIkezSFM5SAR6Lfw1IZBqVaHSYj8FeDZ04DU6KYFKK9OhYVxIlSqrFZT8M
https://lh5.googleusercontent.com/Znc_cdL-3HmaZxzuMNsOSAMa3owVPtSFWCZjrkkHMKcHhfaFVA7lZRlipSljHq_eh4EAopecmrfzBcWnolmisBL24BTqpyp5F2wpVCp6XljFyPwUk-9d1zXUBjd-K5Q5Li4yTZnCjyTK3s9pm6NpFac
About PSYC Corporation (OTCPink: PSYC)
At PSYC Corporation we are integrating media, creativity, and technology to develop and deploy thought-provoking ideas and solutions that are fostering and transforming the approach to some of society’s most pressing matters.
PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, we believe investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.
We are dedicated to a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future.
$PSYC on nice upswing here
DD
$PSYC Under .005 low SS DD thread ⬇️ #investing #mushrooms #psychedelics #thc $TBLT $GOVX $CMRA $SKYX $NWBO $COOP $AVXL $PSWW $ENZC $RGBP $CZNI $AMRN $EBML $VAPR $TSOI $HIRU $IGEX pic.twitter.com/uOEiFqPq3d
— STOCKPRO20 (@stockpro20) July 28, 2022
$PSYC PSYC Teams Up with The Spore Group to Bring Industry-Leading, Psychedelic-Focused Events to Communities Across North AmericaPress Release | 05/24/2022
LAS VEGAS, NV, May 24, 2022 (GLOBE NEWSWIRE) -- PSYC Corporation (OTCPink: PSYC) (“PSYC” or the “Company”) a media leader for the emerging sector of medicinal psychedelics and authorities behind Psychedelic Spotlight, a top ranking psychedelic news and information platform, is pleased to announce that PSYC’s wholly owned subsidiary, Spotlight Media Group, entered into a Collaboration Partnership Agreement with The Spore Group (“TSG”), an organization focused on bridging the gap between education, legislation, regulation, and investing in psychedelics, with the intent of producing industry-leading conferences and events for the emerging psychedelic sector.
Combining the valuable leadership experience of the TSG executive team with the substantial reach and presence established by PSYC’s Psychedelic Spotlight throughout the psychedelic’s community, the companies will kick off their partnership with Sol Pschedelphia, a celebration of the psychedelic revival, to be held at the One Art Community Center in Philadelphia, PA on Friday, June 24th, 2022.
Over the next several months, the companies plan to collaborate on the production of a variety of additional education-inspired events and conferences, both in live and virtual format, in an effort to create informative and thought-provoking conversations surrounding the exciting potential of psychedelic-assisted healing at a grass roots, community-focused level.
“As excited and optimistic as we are here at PSYC over the long-term value potential of the psychedelic space, we recognize the many challenges that are present in terms of exactly how psychedelic-assisted healing will develop a fully legal and effective pathway to accessibility and affordability within communities frequently left behind by Big Pharma,” said PSYC CEO, David Flores. “In recent months, I’ve had the pleasure of joining several, productive conversations with TSG’s Co-Founder and COO, Joe Barnes. We identified a shared passion for creating grassroots movements that begin and end at the very heart of the communities with which we hope to make a positive impact.”
“Moreover,” Flores continued, “this partnership with TSG creates an opportunity for our companies to combine resources and work towards this shared goal in a far more effective manner than independently. I’m also not overlooking the larger, long term value potential this partnership can deliver to each company through an array of additional collaboration opportunities worth exploring together in the second half of 2022.”
As part of this partnership, Psychedelic Spotlight will leverage its branding, marketing and content production expertise to operate as the official promotional partner for any TSG events on which the companies agree to collaborate and will allow for the Company to earn a percentage of gross revenue derived from any such events.
“Mr. Flores has extensive experience in the emerging Psychedelic Industry,” said Joe Barnes, Chief Operating Officer of The Spore Group. “He has built an amazing team which can assist in our endeavor to create a grass-roots movement to educate the public and expand the use of Traditional Plant Medicines.”
In the coming weeks, the companies plan to release additional information related to Sol Pschedelphia through each of their respective platforms, including Psychedelic Spotlight and its related social media channels.
About PSYC Corporation (OTCPink: PSYC)
At PSYC Corporation we are integrating media, creativity, and technology to develop and deploy thought-provoking ideas and solutions that are fostering and transforming the approach to some of society’s most pressing matters.
PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, we believe investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.
We are dedicated to a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future.
Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors, including the effect of COVID-19 and the success of the current vaccine distribution, the adverse effect of the Omicron variant, that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website and is not incorporated by reference into such reports.
Disclaimer: PSYC Corporation does not in any way encourage or condone the use, purchase, sale or transfer of any illegal substances, nor do we encourage or condone partaking in any unlawful activities. We support a harm reduction approach for the purpose of education and promoting individual and public safety. If you are choosing to use psychedelic substances, please do so responsibly.
Corporate Contact:
PSYC Corporation (PSYC)
www.psyccorporation.com
(702) 761-6716
info@psyccorporation.com
OTCPINK: PSYC
$PSYC Psyched Wellness Announces Key Findings from the 90-Day Oral Toxicity Study on AME-1Press Release | 04/26/2022
Toronto, Ontario--(Newsfile Corp. - April 26, 2022) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: DCNPF) (formerly Duncan Park Holdings Corporation) (the "Company" or "Psyched"), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom , is pleased to announce the company KGK, a licensed CRO in Canada, has reported recent findings from the analysis of the intestinal epithelial immune receptor expression study performed in conjunction with the 90-day oral toxicity study with Amanita Muscaria Extract (AME-1). The in vivo study via oral supplementation with AME-1 focused on the potential bioactive effects on the immune receptors Toll-like Receptor-2 (TLR-2) and Dectin-1, both of which are found on the surface of gut epithelial cells. The Toll-like receptors are an important family within the innate immune system and play a vital role in host-defense mechanisms against pathogens. The main function of TLRs is the ability to recognize numerous pathogens, thus activating the host-defense mechanism through the induction of antimicrobial activity. Dectin-1 is a cell surface pathogen recognition receptor that recognizes soluble and /or particulate forms of ß-1,3 or ß-1,6-glucans and, like Toll-like receptors, plays an important role in the host-defense mechanism as well.
The recent results of the in vivo study showed only a modest increase in TLR-2 and Dectin-1 receptors, but this was not a significant finding. It could be interpreted that the challenge of continuous dosing of AME-1 resulted in maximal cell surface expression of TLR-2 and Dectin-1, thus seeing only a modest positive upregulation of cell surface membrane expression. However, the sustained upregulation of both TLR-2 and Dectin-1 receptors indicates innate immune mechanisms that were primed and maintained throughout the course of the 90-day oral study. Furthermore, there was no downregulation of either surface receptor type, nor was there any over priming or stimulating effect which would have negatively impacted the immune system through the production of pro-inflammatory cytokines.
"The importance of these in vivo findings indicates an innate immune priming biological activity, and this is preserved during the 90-day study. The potential priming effect and maintenance result in a more efficient response to an invading pathogen, thus promoting greater gut health and increased health and wellness of the individual. There was no over stimulation or negative effects with long -term use of AME-1 in terms of gut health and wellness. This is another key finding in the further understanding of the effects of AME-1 on health and wellness," says Brian Tancowny, a scientific advisor for Psyched Wellness.
For further information, please contact:
Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
t: 647-400-8494
e: jstevens@psyched-wellness.com
Website: http://www.psyched-wellness.com
Investor Contacts:
Tim Regan/Sophia Bashford
KCSA Strategic Communications
t: (978) 505-2478
e: PsychedWellness@kcsa.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
About Psyched Wellness Ltd.:
Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita Muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.
Cautionary Statement Regarding Forward Looking Information
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward- looking statements contained herein include, but are not limited to, statements regarding: the ability of the Company to develop Amanita Muscaria-derived products; the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and (ii) the uses and potential benefits of Amanita Muscaria.
Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company's ability to continue as a going concern; the Company's ability to continue to develop its mushroom-derived products and associated consumer packaged goods; continued approval of the Company's activities by the relevant governmental and/or regulatory authorities; and the continued growth of the Company.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company's operations; competition within the psychedelics market; risks with respect to the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and the risk that there is no potential benefit of Amanita Muscaria consumption.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
$PSYC PSYC Begins Audit of 2021 FinancialsPress Release | 04/19/2022
LAKE OSWEGO, OR, April 19, 2022 (GLOBE NEWSWIRE) -- PSYC Corporation (OTCPink: PSYC) (“PSYC” or the “Company”) a media leader for the emerging sector of medicinal psychedelics and authorities behind Psychedelic Spotlight, a top ranking psychedelic news and information platform, is pleased to announce that on the heels of successfully completing the audit of its 2020 financials last month, the Company has now commenced with the audit of its 2021 financials.
M&K CPAS, PLLC will once again serve as the auditing firm for the Company, who is eager to bring its audited financial statements current through December 31, 2021. Thereafter, it is the Company’s intention to maintain current and fully audited financials on a quarterly basis as it continues working towards, but cannot guarantee, an eventual up listing to the OTCQB by way of filing its Form-10 registration statement.
“Swiftly moving into the audit of our 2021 financials, after successfully completing our 2020 audit, represents another example of our unwavering commitment to keeping PSYC on track for a potential up listing from the pink sheets to the OTCQB in the most reasonable time frame possible,” said PSYC CEO, David Flores. “Up listing is something we continue to view as an essential part of the credibility and overall value we are determined to establish for PSYC and our shareholders in the months and years ahead. We look forward to tackling the 2021 audit while simultaneously solidifying key objectives, such as our monetization strategies, that we believe are equally important to PSYC’s growth potential.”
PSYC CFO Craig Schlesinger added, “PSYC’s commitment to transparency and integrity will only be strengthened upon completion of the audited 2021 financial statements. Becoming and remaining a fully current SEC reporting company fulfills a crucial step in the up listing process, as well as establishing trust and credibility with the investing community as we continually execute on our fundamental growth strategies. I believe in our team’s commitment to tangible execution and building long term value for PSYC, our loyal shareholders, and the communities we serve.”
About PSYC Corporation (OTCPink: PSYC)
At PSYC Corporation we are integrating media, creativity, and technology to develop and deploy thought-provoking ideas and solutions that are fostering and transforming the approach to some of society’s most pressing matters.
PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, we believe investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.
We are dedicated to a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future.
Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors, including the effect of COVID-19 and the success of the current vaccine distribution, the adverse effect of the Omicron variant, that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website and is not incorporated by reference into such reports.
Disclaimer: PSYC Corporation does not in any way encourage or condone the use, purchase, sale or transfer of any illegal substances, nor do we encourage or condone partaking in any unlawful activities. We support a harm reduction approach for the purpose of education and promoting individual and public safety. If you are choosing to use psychedelic substances, please do so responsibly.
Corporate Contact:
PSYC Corporation (PSYC)
www.psyccorporation.com
(702) 239-1919
info@psyccorporation.com
OTCPINK: PSYC
$PSYC Psyched Wellness Announces Share Purchase by Chief Executive Officer, Jeffrey StevensPress Release | 04/19/2022
Toronto, Ontario--(Newsfile Corp. - April 19, 2022) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched") a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom is pleased to announce that CEO, Director, and Co-Founder, Jeffrey Stevens, has purchased 321,000 shares of the Company in the open market at $0.125/share, for total proceeds of $40,125.00.
"I am thrilled to take this opportunity to add to my open-market share purchases from last year," says Jeffrey Stevens, CEO of the Company. "Our stock price has increased in the last quarter alone. In addition to our market growth, we have experienced a number of recent successes that have strengthened our position and are excited to be approved to launch our flagship product, Calm, in the United States of America. Our stock price doesn't reflect this growth yet-but it will. We have been working diligently to position and grow our business, and I believe that we are on track to deliver sustainable, long-term shareholder value."
For further information, please contact:
Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
t: 647-400-8494
e: jstevens@psyched-wellness.com
Website: http://www.psyched-wellness.com
Investor Contacts:
Tim Regan/Sophia Bashford
KCSA Strategic Communications
t: (978) 505-2478
e: PsychedWellness@kcsa.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
About Psyched Wellness Ltd.:
Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita Muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.
Cautionary Statement Regarding Forward-Looking Information
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the ability of the Company to develop Amanita Muscaria-derived products; the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and (ii) the uses and potential benefits of Amanita Muscaria.
Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company's ability to continue as a going concern; the Company's ability to continue to develop its mushroom-derived products and associated consumer packaged goods; continued approval of the Company's activities by the relevant governmental and/or regulatory authorities; and the continued growth of the Company.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company's operations; competition within the psychedelics market; risks with respect to the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and the risk that there is no potential benefit of Amanita Muscaria consumption.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Wrong board. $PSYCF is not $PSYC on OTC.
$PSYC Psyched Wellness Unveils New Product Name and Visual Identity ElementsPress Release | 03/30/2022
Toronto, Ontario--(Newsfile Corp. - March 30, 2022) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched"), a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, has unveiled its official branding and visuals for its Amanita Muscaria Extract (AME-1) today as the company prepares for a Spring launch in the USA to meet consumer demand for ethically sourced, high-quality Amanita Muscaria products. Introduced as the company's flagship product, Psyched Wellness will begin using the brand name 'Calm' for its proprietary Amanita Muscaria extract. The product, which is being investigated as a sleep-aid, is said to induce feelings of relaxation and balance and should be taken prior to periods of rest or recovery.
"The Calm product visual is a beautiful, gender-neutral design that we loved from the moment we saw it," says Psyched's Chief Executive Officer Jeffrey Stevens. "But we wanted our shareholders and customers to be involved in the selection process for Calm's look and feel. Their ideas and perspective matter to us, and they helped us make the decision about the look of Calm going forward. It was such a great process, full of lively conversation and incredibly thoughtful input. From this dialogue, we are excited to boldly step into the future together."
Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6579/118529_9d76226d443c8b65_002.jpg
Psyched Wellness unveils the first label design for the launch of AME-1 Tinctures - Winning Design
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6579/118529_9d76226d443c8b65_002full.jpg
For further information, please contact:
Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
t: (647) -400-8494
e: jstevens@psyched-wellness.com
Website: http://www.psyched-wellness.com
Investor Contacts:
Tim Regan/Sophia Bashford
KCSA Strategic Communications
t: (347) 387-6788978) 505-2478
e: PsychedWellness@kcsa.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
About Psyched Wellness Ltd.:
Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita Muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.
Cautionary Statement Regarding Forward Looking Information
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward- looking statements contained herein include, but are not limited to, statements regarding: the ability of the Company to develop Amanita Muscaria-derived products; the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and (ii) the uses and potential benefits of Amanita Muscaria.
Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company's ability to continue as a going concern; the Company's ability to continue to develop its mushroom-derived products and associated consumer packaged goods; continued approval of the Company's activities by the relevant governmental and/or regulatory authorities; and the continued growth of the Company.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company's operations; competition within the psychedelics market; risks with respect to the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and the risk that there is no potential benefit of Amanita Muscaria consumption.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
PSYC Someone wake me if we ever hit a penny.
Global Trac Solutions Inc. changed to PSYC Corporation:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
$PSYC Psyched Wellness Announces Launch of New Logo, Branding, and Website, Prepares to Release Industry-First Amanita Muscaria Tincture
Press Release | 02/01/2022
Toronto, Ontario--(Newsfile Corp. - February 1, 2022) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched") a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that the Company has successfully launched its new logo, branding, and website.
This is a major milestone for the only publicly traded company focusing on the Amanita Muscaria (AM) mushroom, as the Company prepares to launch its industry-first tincture product in the front half of 2022.
The refreshed branding draws more attention to the iconic red-and-white AM fungi that is easily the most recognizable image of a psychedelic mushroom in popular culture. By displaying the Amanita so prominently, Psyched Wellness is staking its claim as the clear industry leader relating to the study, education, and commercialization of safe to use AM products via their proprietary mushroom extract, AME-1.
Psyched's new website demonstrates the Company's consideration and homage to the history of the mushroom, while incorporating modern information, aesthetics, and eCommerce capabilities for ease of use by consumers. The logo and website were developed with the support and guidance of external agencies, DACs Marketing and Spark Advocacy.
The Company's AM tincture will be available over the counter, without a prescription, and is described as having "soothing and calming effects". Psyched plans to release pre-sale information and product visuals in late February.
Jeffrey Stevens, Chief Executive Officer of Psyched Wellness, said, "We have been working hard to prepare for the industry-first launch of our tincture to the consumer-packaged goods market, which we are excited to share with consumers. Our Amanita Muscaria tincture is naturally derived and can aid stress relief, relaxation, and restful sleep. Now that the groundwork for the product launch is nearing completion, we can turn our attention to the Company's next phase, which is to generate sustainable and growing revenue going forward."
For further information, please contact:
Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
t: 647-400-8494
e: jstevens@psyched-wellness.com
Website: http://www.psyched-wellness.com
Investor Contacts:
Tim Regan/Sophia Bashford
KCSA Strategic Communications
t: (978) 505-2478
e: PsychedWellness@kcsa.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
About Psyched Wellness Ltd.:
Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita Muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.
Cautionary Statement Regarding Forward Looking Information
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward- looking statements contained herein include, but are not limited to, statements regarding: the ability of the Company to develop Amanita Muscaria-derived products; the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and (ii) the uses and potential benefits of Amanita Muscaria.
Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company's ability to continue as a going concern; the Company's ability to continue to develop its mushroom-derived products and associated consumer packaged goods; continued approval of the Company's activities by the relevant governmental and/or regulatory authorities; and the continued growth of the Company.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company's operations; competition within the psychedelics market; risks with respect to the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and the risk that there is no potential benefit of Amanita Muscaria consumption.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Toronto, Ontario--(Newsfile Corp. - February 1, 2022) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched") a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that the Company has successfully launched its new logo, branding, and website.
PSYC is not PSYCF...I think OTCM made a typo...two diff companies, diff address...etc.
Reps. Daniel Pae (R) and Logan Phillips (R) from Oklahoma, filed bills meant to promote research into the therapeutic potential of psilocybin. The proposals are designed to give the legislature different options with similar scientific study objectives, but a key difference is that Pae’s would also decriminalize possession of up to one-and-a-half ounces of psilocybin by making it punishable by a fine, reported Marijuana Moment.
Rep. Pae’s proposal would explicitly authorize research institutes to obtain psilocybin and use it for investigations into treatment efficacy for 10 different conditions, including post-traumatic stress disorder (PTSD), severe depression and opioid use disorder. Eligible institutes would need to obtain a license for the state Department of Health.
I’m trying to transfer the stock to a broker, what company will take this worthless stock?
$PSYC PSYC’s Psychedelic Spotlight Nets 600K+ Page Views in December & Launches Revamped Site
Press Release | 01/12/2022
LAKE OSWEGO, OR, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) a media leader for the emerging sector of medicinal psychedelics, and authorities behind Psychedelic Spotlight, a top ranking psychedelic news and information platform, is pleased to announce that its Psychedelic Spotlight media platform netted nearly 620K page views in the month of December 2021. This marks the third consecutive month in which the site realized more than half-a-million page views and further reinforced its evolution into a leading news and information hub for the medicinal psychedelic industry.
In addition to the site’s impressive growth streak, the Company also completed the launch of a revamped version of its platform in late December. It’s intent, amongst other ongoing quality control improvements, is to provide visitors with a streamlined user experience featuring faster page loads, more organized user-friendly layout/interface, and a visual aesthetic in-tune with Psychedelic Spotlight’s new brand identity features.
On the backend, the Company devoted considerable time and effort to integrating a variety of SEO optimization features designed to help content published by Psychedelic Spotlight’s talented team of writers and digital content creators perform more effectively and further solidify the site’s top ranking for psychedelic news on Google.
“Over the past several months, our Psychedelic Spotlight website became the foundation of our monetization initiatives,” said PSYC CEO, David Flores. “Continuing to invest in strategies that are focused on contributing to its growth and enhancing its ability to provide an optimal user experience is something that, we believe, should be regarded as a top priority, given the value it demonstrated capable of creating for PSYC as a media leader for medicinal psychedelics. Much of our focus in the coming months will be on expanding our content production and introducing new content material designed to attract a larger audience across the psychedelic and health and wellness communities. I’m very excited for the future of PSYC.”
“I am incredibly proud and excited about the growth and progress we've witnessed throughout the past few months, especially in Q4,” said Psychedelic Spotlight Media Director, Swati Sharma. “With our approach to psychedelic news and content expanding, we found that we've hit the nail on the head to catalyze this process by incorporating the stories and information that our audience is most excited for. Namely, our progressive shift from being a business and investment focused platform to a psychedelic cultural news hub has allowed for us to reach a larger audience base, resulting in impressive growth throughout our website. This, along with a recent website redesign and more attention to refining our overall brand has been an exciting way for us to start the new year as we continue to define and achieve our collective goals for both Psychedelic Spotlight and PSYC.”
About Global Trac Solutions, Inc. (OTCPink: PSYC)
At Global Trac Solutions we are integrating media, creativity, and technology to develop and deploy thought-provoking ideas and solutions that are fostering and transforming the approach to some of society’s most pressing matters.
PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, we believe investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.
We are dedicated to a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future.
Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors, including the effect of COVID-19 and the success of the current vaccine distribution, the adverse effect of the Omicron variant, that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website and is not incorporated by reference into such reports.
Disclaimer: Global Trac Solutions, Inc. does not in any way encourage or condone the use, purchase, sale or transfer of any illegal substances, nor do we encourage or condone partaking in any unlawful activities. We support a harm reduction approach for the purpose of education and promoting individual and public safety. If you are choosing to use psychedelic substances, please do so responsibly.
Corporate Contact:
Global Trac Solutions, Inc. (PSYC)
www.globaltracsolutions.com
(702) 239-1919
psyc@globaltracsolutions.com
OTCPINK: PSYC
THIS IS NOT "PSYCHED WELLNESS" BOARD!!!!!!!
Psyched wellness is PSYCF.
It is PYSC.CA in Canada
$PSYC PSYC Strengthens Leadership Team with Finance & Operations Advisory Board Appointments
Press Release | 01/04/2022
LAKE OSWEGO, OR, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) a media leader for the emerging sector of medicinal psychedelics, and authorities behind Psychedelic Spotlight, a top ranking psychedelic news and information platform, is pleased to announce the addition of Christopher Bitonti and Craig Schlesinger to its Advisory Board.
Following the Company’s success in 2021 with establishing its Psychedelic Spotlight platform as a premiere news and media source for the emerging medicinal psychedelic industry, PSYC is determined to expand on this momentum in 2022 by initiating a concerted effort focused on reshaping its corporate structure from the ground up and with the intent of developing PSYC into an industry powerhouse for media and marketing.
Through the additions of Mr. Bitonti and Mr. Schlesinger to its Advisory Board, the Company will look to leverage their combined professional knowledge and experience, which spans across the respective fields of corporate finance, media marketing, and business operations, to further expand on its ongoing monetization initiatives associated with Psychedelic Spotlight, help identify untapped monetization opportunities, and begin the process of strengthening the core of it is corporate structure.
“I truly believe we are at a critical juncture in the growth and evolution of PSYC that is every bit as challenging as it is exciting,” said Global Trac Solutions, Inc. CEO, David Flores. “As elated as I am to have established Psychedelic Spotlight into what I believe is a tangible asset for PSYC with an enormous amount of exciting growth potential ahead of it, I recognize the importance of developing and implementing a plan focused on legitimizing and realizing the value potential of PSYC as a publicly traded media leader for the psychedelic industry. With this in mind, I am extremely pleased to add Mr. Bitonti and Mr. Schlesinger to our growing Advisory Board. The respective knowledge, insight, and expertise they bring should prove to be highly beneficial in helping us initiate this next, important phase in our corporate evolution.”
Mr. Bitonti joins PSYC’s Advisory Board bringing with him over a decade of experience in media and live entertainment. He will draw on his background both as a journalist and previously as the National Director of Marketing for the Dayglow brand, which includes Brooklyn Bowl venues, Relix Media, and the live streaming platform FANS.live. In his advisory capacity, Mr. Bitonti will be helping build organizational infrastructure for PSYC with a focus on creating efficiencies across marketing efforts and increasing brand awareness as the company continues to scale.
"I am thrilled to join the Advisory Board of a Company that is truly pioneering a new media space with limitless branding potential,” said Mr. Bitonti. “The public interest in consuming quality psychedelic news and information is an extraordinary trend that can’t be ignored. I believe the knowledge I've gained from launching multiple media brands, building their marketing assets and organizations from the ground up, and establishing operational and brand consistency will help boost the already amazing work being done by the PSYC team to the next level."
Mr. Schlesinger, meanwhile, is a C-Suite consultant with 20 years’ experience specializing in public finance and corporate financial management since graduating from the University of Florida in 2003. His contributions extend across various industries at companies such as Viacom, Smile Direct Club, MGM Mandalay Bay, MedHost, AMG PhyMed, My Office Products, and Consolidated Resorts.
In his advisory capacity, Mr. Schlesinger will also serve as Acting VP of Finance for PSYC and for the intended purpose of working closely with PSYC CEO, David Flores, on retooling the Company’s corporate financial structure and identifying areas to increase corporate governance.
“I spent the better part of two decades consulting C-Suites across multiple industries; specializing in public finance, financial management, strategic development, arbitrage, treasury functions, and analytics. Psychedelics are the exciting new frontier, disrupting, evolving, and adapting to meet today’s mental health, wellness, and quality of life challenges. PSYC is at the forefront of this movement, and I’m looking forward to cleaning up the Company balance sheet, raising public market awareness of the stock, building equity financing to sustain and expand operations, identifying optimal capital structures to suit our new revenue mix, and delivering value to our shareholders and communities we serve. It’s a privilege to join such a dedicated, talent-rich team.”
About Global Trac Solutions, Inc. (OTCPink: PSYC)
At Global Trac Solutions we are integrating media, creativity, and technology to develop and deploy thought-provoking ideas and solutions that are fostering and transforming the approach to some of society’s most pressing matters.
PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, we believe investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.
We are dedicated to a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future.
Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors, including the effect of COVID-19 and the success of the current vaccine distribution, the adverse effect of the Omicron variant, that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website and is not incorporated by reference into such reports.
Disclaimer: Global Trac Solutions, Inc. does not in any way encourage or condone the use, purchase, sale or transfer of any illegal substances, nor do we encourage or condone partaking in any unlawful activities. We support a harm reduction approach for the purpose of education and promoting individual and public safety. If you are choosing to use psychedelic substances, please do so responsibly.
Corporate Contact:
Global Trac Solutions, Inc. (PSYC)
www.globaltracsolutions.com
(702) 239-1919
psyc@globaltracsolutions.com
OTCPINK: PSYC
From The Daily Mail.
An active ingredient in magic mushrooms could help treat mental health disorders including PTSD, research suggests.
Scientists say that small doses of the psychedelic drug psilocybin, found in 'magic' mushrooms are not only good at easing disorders resistant to treatment but they also have no short or long-term side effects in healthy people.
Researchers in a study led by the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King's College London, found that the drug can be given safely in doses of either 10mg or 25mg to up to six patients.
Looks like they are running out of fake shares to sell
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |